FibroBiologics, Inc.
FBLG
$1.06
-$0.09-7.83%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 11.61% | -0.68% | -4.68% | -1,055.60% | -618.71% |
| Total Depreciation and Amortization | -21.84% | 47.20% | 52.94% | 61.54% | 47.14% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 109.63% | -41.01% | 678.29% | 168.80% | 109.34% |
| Change in Net Operating Assets | 97.91% | 84.50% | -378.85% | 231.82% | -203.46% |
| Cash from Operations | 17.39% | 17.27% | -2.93% | -52.42% | -104.62% |
| Capital Expenditure | -- | -- | 100.00% | 45.45% | -222.73% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | 100.00% | 45.45% | -222.73% |
| Total Debt Issued | -100.00% | -- | -100.00% | -- | -- |
| Total Debt Repaid | -- | -- | -2,856.52% | -- | -- |
| Issuance of Common Stock | -- | -- | 14,544.44% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 21.69% | -- | -65.81% | -100.00% | 2,643.60% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,042.13% | 35.84% | -99.56% | -314.56% | 108.15% |